作者
Alexander Starodub,Allyson J. Ocean,Wells A. Messersmith,Vincent J. Picozzi,Michael J. Guarino,Aditya Bardia,Sajeve Samuel Thomas,Jordan D. Berlin,Manish A. Shah,Pius P. Maliakal,William A. Wegener,Robert M. Sharkey,Francois E. Wilhelm,David M. Goldenberg
摘要
3546 Background: Sacituzumab govitecan (IMMU-132) is a conjugate of a humanized anti-Trop-2 (trophoblast cell-surface antigen) coupled site-specifically to SN-38 (7.6 moles SN-38/IgG), an active metabolite of irinotecan, using a proprietary linker. Trop-2 is widely expressed in most epithelial cancers, including gastrointestinal (GI) tumors, and therefore the safety and efficacy of this new ADC is being examined in esophageal (EAC), gastric (GC), pancreatic (PC), and colorectal cancers (CRC). Methods: A Phase I/II clinical trial (ClinicalTrials.gov, NCT01631552) was initiated in patients with diverse epithelial cancers, administering IMMU-132 i.v. on days 1 and 8 of 21-day treatment cycles. Treatment was continued based on tolerance or until progression. Results: In Phase I, 23 assessable pts were given 8, 10, 12, or 18 mg/kg. Dose-limiting neutropenia occurred at 18 mg/kg. For Phase II, enrollment was expanded to multiple cycles of 8 and 10 mg/kg. Safety data from 123 patients given 8-10 mg/kg showed neutropenia (G3, 18%; G4, 6%), febrile neutropenia (G3, 2%; G4, 2%), but only 3% G3 diarrhea (no G4). Other G3 toxicities included anemia (6%), fatigue (5%), leucopenia (2%), vomiting (2%), and asthenia (1%). No pt developed antibodies to the ADC. Among assessable patients by RECIST 1.1, of 15 EAC pts (median 3 prior therapies), 2 had PR (1 confirmed, duration 6 mo, 1 continuing; 13% ORR), and 7 (46%) SD (median time to progression (TTP) = 5.0 mo). All 3 GC pts had SD (one continuing for 11 mo). Of 14 PC pts (median 2 prior therapies), 7 (50%) had SD with a median TTP of 3.4 mo. In 26 CRC pts (median 4 prior therapies), there was 1 PR (confirmed, duration 10 mo), 14 SD (54%), and a median TTP of 5.1 mo. Conclusions: Repeated cycles of IMMU-132 monotherapy are well tolerated with seemingly more favorable neutropenia and diarrhea rates compared to irinotecan. Objective responses in esophageal cancer and extended stabilization in colorectal cancers are encouraging for this monotherapy. The manageable toxicity and promising disease control in these pts warrant further study in combination with other appropriate agents for GI malignancies. Clinical trial information: NCT01631552.